What do we know about rapamycin as an anti-ageing agent in humans?
Rapamycin shows early positive signals in humans for immune function and skin, but long-term safety is unknown and side effects such as infections and unfavourable blood lipids are a real risk. Use outside a clinical trial is premature.
Rapamycin extended lifespan in mice consistently and convincingly, including in genetically diverse animals. Part of that effect is probably explained by the drug's suppression of cancer, the leading cause of death in mice, and not solely by a slowing of the ageing process itself. Whether this also applies to humans, nobody knows.
In humans, the first randomised studies are modest but positive. Everolimus (a related compound) improved the response to the influenza vaccine in older adults by roughly 20%, and reduced signs of ageing in the immune system. A small study using rapamycin cream on the skin showed a decline in a cellular ageing marker and an increase in collagen, but well over half of the participants dropped out, so those findings have limited reliability.
A 2024 systematic review of 19 studies concludes that rapamycin and related compounds produce modest to moderate improvements in parameters of the immune system, the cardiovascular system, and the skin. No significant effects were found in humans for muscles, hormones, or the nervous system. The effects on the kidneys, lungs, digestive system, and reproductive system have not yet been studied at all in humans.
Side effects are a genuine concern. In people with age-related diseases, rapamycin and related compounds were associated with more infections and unfavourable blood lipids (higher cholesterol and triglyceride levels). In healthy individuals, no serious side effects were reported in the available studies, but those data partly come from a survey of 333 people using the drug on their own initiative, without a control group or objective measurement. Long-term safety in humans has simply not yet been studied.
Rapamycin is already being used off-label on a small scale for ageing prevention, but the clinical evidence in humans remains limited. Randomised studies are lacking for most outcomes, and nobody knows how many systems in the body are affected. It is too early to use this drug outside a clinical setting.
One systematic review (PMID 38310895), two randomised studies (PMID 25540326, 31761958), one observational self-report study (PMID 37191826), and three reviews on animal studies and mechanisms (PMID 23454761, 25015322, 28548953, 31586989). No long-term RCTs in humans are available.
Does rapamycin help people live longer in good health?
Rapamycin demonstrably extends the lifespan of mice and other animals, but whether the same holds true for humans has not yet been supported by large clinical studies. Do not use it without medical supervision: side effects are real and many organ systems have barely been studied in humans.
Will a doctor prescribe rapamycin?
Most doctors will not prescribe rapamycin to healthy people to slow ageing, simply because the evidence for doing so is still lacking. For certain rare conditions a specialist may consider it off-label, but always with a careful weighing of the risks.
Is rapamycin found in food, or can you get it naturally through your diet?
Rapamycin is not found in food and cannot be obtained through your diet. It is a medicine used only under medical supervision, due to the real risk of immune suppression.
Can anyone take rapamycin?
Rapamycin is a powerful drug with serious side effects, including reduced immune function and blood sugar disturbances, and is not suitable for independent use outside medical supervision.
Does rapamycin improve skin aging?
Topical rapamycin showed promising signs for skin ageing in a small study, but the evidence is still too thin to justify self-application.
Can rapamycin reverse or prevent grey hair?
Rapamycin shows interesting effects on pigmentation in the lab and in a rare hereditary disease, but there is no evidence whatsoever that it reverses or prevents grey hair in healthy people.